Myriad Genetics Expands MyChoice Test Access for Prostate Cancer Patients in Japan

The molecular diagnostics company's tumor-based test is now reimbursed for prostate cancer patients, broadening access to genomic insights.

Apr. 14, 2026 at 1:37pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray image revealing the intricate internal structure of a human prostate gland, with glowing blue and violet lines and shapes against a dark background, conceptually representing the advanced genomic analysis capabilities of the MyChoice test.The expanded access to Myriad's MyChoice test for prostate cancer patients in Japan aims to unlock new genomic insights that can guide personalized treatment decisions.Salt Lake City Today

Myriad Genetics announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for the PARP inhibitor drug Lynparza®. This expands access to the MyChoice test, which was previously only reimbursed in Japan for breast and ovarian cancer patients, allowing clinicians to now determine homologous recombination deficiency (HRD) status and BRCA1/2 status for prostate cancer patients as well.

Why it matters

The approval of the MyChoice test for prostate cancer patients in Japan is significant, as it provides a new testing option to identify those who may benefit from PARP inhibitor treatments. This is especially important for the over 100,000 men newly diagnosed with prostate cancer in Japan each year, a portion of whom will progress to metastatic castration-resistant prostate cancer (mCRPC).

The details

The MyChoice Test offers comprehensive homologous recombination deficiency (HRD) testing, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks. This makes them more susceptible to DNA-damaging drugs like PARP inhibitors. The test analyzes the BRCA1 and BRCA2 genes and uses three proprietary technologies to assess HRD status. It is now approved for use in breast, ovarian, and prostate cancer indications in Japan.

  • Myriad Genetics announced the MHLW approval on April 14, 2026.
  • The MyChoice test was previously only reimbursed in Japan for breast and ovarian cancer patients.

The players

Myriad Genetics Inc.

A leader in molecular diagnostic testing and precision medicine, and the developer of the MyChoice test.

Japan's Ministry of Health, Labour and Welfare (MHLW)

The government agency that approved the use of the MyChoice test as a companion diagnostic for prostate cancer patients in Japan.

Dr. Hiroji Uemura

A Project Professor in the Department of Urological Oncology at Yokohama City University Graduate School of Medicine, who commented on the significance of the MyChoice test approval for prostate cancer patients in Japan.

Got photos? Submit your photos here. ›

What they’re saying

“Expanding the MyChoice test into prostate cancer marks an important milestone for Myriad Genetics in Japan. Previously, MyChoice testing was only reimbursed under Japan's National Health Insurance (NHI) for breast and ovarian cancer patients, so this new approval broadens access to critical genomic insights that help clinicians make informed treatment decisions for their patients.”

— Brian Donnelly, Chief Commercial Officer, Myriad Genetics

“The reimbursement approval of MyChoice for prostate cancer provides a new testing option for patients with castration-resistant prostate cancer. In addition to the previously available germline BRCA1/2 testing, the inclusion of tumor-based testing is expected to expand the number of patients who may benefit from treatment with PARP inhibitors.”

— Dr. Hiroji Uemura, Project Professor, Department of Urological Oncology, Yokohama City University Graduate School of Medicine

What’s next

Myriad Genetics plans to continue expanding access to the MyChoice test for additional cancer indications in Japan, further broadening the availability of this precision diagnostics tool.

The takeaway

The approval of the MyChoice test for prostate cancer patients in Japan represents an important advancement in precision oncology, giving clinicians a new tool to identify those who may benefit from targeted PARP inhibitor treatments. This highlights Myriad's commitment to bringing high-value molecular tests to the Japanese market and improving patient outcomes.